Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Phase 1
Terminated
- Conditions
- Relapsed/Recurrent GBM (Phase 2)Solid Tumors (Phase 1)
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Proximagen, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02765165
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
News
No news found